Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer.

ABSTRACT:

Background

Hormone receptor (HR)-negative, HER2-positive (also called HER2-enriched) breast cancer has no worse prognosis than other breast cancers if it is treated with HER2-targeted therapy. Medicaid expansion under the Affordable Care Act (ACA) has been shown to be associated with improved access to care and outcomes for many cancers, but its association with receipt of care for HR-negative, HER2-positive breast cancer is unknown. We examined the association of Medicaid expansion with receipt of guideline-concordant treatment, time to treatment initiation, and survival among nonelderly women newly diagnosed with HR-negative, HER2-positive breast cancer.

Patients and methods

Women aged 18 to 62 years newly diagnosed with HR-negative, HER2-positive breast cancer between 201

SUBMITTER: Shi KS 

PROVIDER: S-EPMC12664081 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature